Transasia Bio-Medicals Ltd. announced the formal inauguration of its state-of-the-art medical device manufacturing facility in the Andhra Pradesh MedTech Zone (AMTZ) on Thursday.
The largest of its kind in Asia, covering over 35,000 square meters, ErbaLisa will manufacture COVID-19 IgG ELISA test kits, RT-PCR kits and rapid test kits for India and other emerging markets.
The new facility was appointed by Minister of Industry, Trade and IT, Mekapati Goutham Reddy, Chairman of the Indian Telecommunications Regulatory Authority (TRAI), PD Vaghela, Scientific Secretary to the Chief Scientific Advisor to the Government of India, Arabinda Mitra, Special Chief Secretary of Government (Industry and Trade) R. Karikal Valven in the presence of MD and CEO of AMTZ Jitendra Sharma, founder and chairman of the Transasia-Erba International group of companies Suresh Vazirani and vice-president for R&D reagents at Transasia Bio-Medicals Ltd. Manoj Chugh.
The AMTZ unit is Transasia’s fifth production facility in India after Baddi (Himachal Pradesh), Daman, Sikkim and Mumbai.
The new facility was built with an initial investment of over £ 30 million. The integrated facility, with an annual capacity of 2 million molecular and serological test kits, has facial recognition systems, cold rooms, storage areas, BSL-II / BSL-III quality clean rooms, large freeze dryers, protein purification equipment, advanced QC equipment and automated equipment machines.
According to a statement posted here on Thursday, the facility will significantly reduce India’s current import dependency for such test kits.